Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Short communication

Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1

Authors: Louise van der Weyden, Mark J Arends, Alistair G Rust, George Poulogiannis, Rebecca E McIntyre, David J Adams

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

CADM1 encodes an immunoglobulin superfamily (IGSF) cell adhesion molecule. Inactivation of CADM1, either by promoter hypermethylation or loss of heterozygosity, has been reported in a wide variety of tumor types, thus it has been postulated as a tumor suppressor gene.

Findings

We show for the first time that Cadm1 homozygous null mice die significantly faster than wildtype controls due to the spontaneous development of tumors at an earlier age and an increased tumor incidence of predominantly lymphomas, but also some solid tumors. Tumorigenesis was accelerated after irradiation of Cadm1 mice, with the reduced latency in tumor formation suggesting there are genes that collaborate with loss of Cadm1 in tumorigenesis. To identify these co-operating genetic events, we performed a Sleeping Beauty transposon-mediated insertional mutagenesis screen in Cadm1 mice, and identified several common insertion sites (CIS) found specifically on a Cadm1-null background (and not wildtype background).

Conclusion

We confirm that Cadm1 is indeed a bona fide tumor suppressor gene and provide new insights into genetic partners that co-operate in tumorigenesis when Cadm1-expression is lost.
Appendix
Available only for authorised users
Literature
1.
Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH, Murakami Y: TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet. 2001, 27: 427-430. 10.1038/86934CrossRefPubMed
2.
Murakami Y: Involvement of a cell adhesion molecule. TSLC1/IGSF4, in human oncogenesis. Cancer Sci. 2005, 96: 543-552. 10.1111/j.1349-7006.2005.00089.xCrossRefPubMed
3.
Liang QL, Chen GQ, Li ZY, Wang BR: Function and histopathology of a cell adhesion molecule TSLC1 in cancer. Cancer Invest. 2011, 29: 107-112. 10.3109/07357907.2010.543211CrossRefPubMed
4.
Mao X, Seidlitz E, Truant R, Hitt M, Ghosh HP: Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene. 2004, 23: 5632-5642. 10.1038/sj.onc.1207756CrossRefPubMed
5.
Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, Murakami Y, Guan XY, Sham JS, Chua D, Protopopov AI, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML: TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res. 2006, 66: 9385-9392. 10.1158/0008-5472.CAN-06-0590CrossRefPubMed
6.
van der Weyden L, Arends MJ, Chausiaux OE, Ellis PJ, Lange UC, Surani MA, Affara N, Murakami Y, Adams DJ, Bradley A: Loss of TSLC1 causes male infertility due to a defect at the spermatid stage of spermatogenesis. Mol Cell Biol. 2006, 26: 3595-3609. 10.1128/MCB.26.9.3595-3609.2006PubMedCentralCrossRefPubMed
7.
Takayanagi Y, Fujita E, Yu Z, Yamagata T, Momoi MY, Momoi T, Onaka T: Impairment of social and emotional behaviors in Cadm1-knockout mice. Biochem Biophys Res Commun. 2010, 396: 703-708. 10.1016/j.bbrc.2010.04.165CrossRefPubMed
8.
De Maria A, Shi Y, Luo X, Van Der Weyden L, Bassnett S: Cadm1 expression and function in the mouse lens. Invest Ophthalmol Vis Sci. 2011, 52: 2293-2299. 10.1167/iovs.10-6677PubMedCentralCrossRefPubMed
9.
Giangreco A, Jensen KB, Takai Y, Miyoshi J, Watt FM: Necl2 regulates epidermal adhesion and wound repair. Development. 2009, 136: 3505-3514. 10.1242/dev.038232PubMedCentralCrossRefPubMed
10.
Paulsson K, An Q, Moorman AV, Parker H, Molloy G, Davies T, Griffiths M, Ross FM, Irving J, Harrison CJ, Young BD, Strefford JC: Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia. Br J Haematol. 2009, 144: 838-847. 10.1111/j.1365-2141.2008.07523.xCrossRefPubMed
11.
Fu L, Gao Z, Zhang X, Tsang YH, Goh HK, Geng H, Shimizu N, Tsuchiyama J, Srivastava G, Tao Q: Frequent concomitant epigenetic silencing of the stress-responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma. Int J Cancer. 2009, 124: 1572-1578. 10.1002/ijc.24123CrossRefPubMed
12.
Heddle JA: A rapid in vivo test for chromosomal damage. Mutat Res. 1973, 18: 187-190. 10.1016/0027-5107(73)90035-3CrossRefPubMed
13.
Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA: Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005, 436: 272-276. 10.1038/nature03681CrossRefPubMed
14.
March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M, van der Weyden L, Berns A, Gadiot J, Uren A, Kemp R, Arends MJ, Wessels LF, Winton DJ, Adams DJ: Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet. 2011, 43: 1202-1209. 10.1038/ng.990PubMedCentralCrossRefPubMed
15.
Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA: ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol. 2006, 28: 259-272.PubMed
16.
Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, Mann G, Kauer M, Rainer J, Kofler R, Hall A, Metzler M, Meyer LH, Meyer C, Harbott J, Marschalek R, Strehl S, Haas OA, Panzer-Grümayer R: ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood. 2011, 117: 2658-2667. 10.1182/blood-2010-03-275347CrossRefPubMed
17.
Wang LB, Zheng S, Zhang SZ, Peng JP, Ye F, Fang SC, Wu JM: Expression of ST13 in colorectal cancer and adjacent normal tissues. World J Gastroenterol. 2005, 11: 336-339.PubMedCentralCrossRefPubMed
18.
Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM: Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res. 2001, 7: 551-557.PubMed
19.
Dror Y, Ward AC, Touw IP, Freedman MH: Combined corticosteroid/granulocyte colony-stimulating factor (G-CSF) therapy in the treatment of severe congenital neutropenia unresponsive to G-CSF: Activated glucocorticoid receptors synergize with G-CSF signals. Exp Hematol. 2000, 28: 1381-1389. 10.1016/S0301-472X(00)00544-0CrossRefPubMed
20.
21.
Ohno H, Hirabayashi S, Kansaku A, Yao I, Tajima M, Nishimura W, Ohnishi H, Mashima H, Fujita T, Omata M, Hata Y: Carom: a novel membrane-associated guanylate kinase-interacting protein with two SH3 domains. Oncogene. 2003, 22: 8422-8431. 10.1038/sj.onc.1206996CrossRefPubMed
22.
Biederer T, Sara Y, Mozhayeva M, Atasoy D, Liu X, Kavalali ET, Südhof TC: SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science. 2002, 297: 1525-1531. 10.1126/science.1072356CrossRefPubMed
23.
24.
Luque-García JL, Martínez-Torrecuadrada JL, Epifano C, Cañamero M, Babel I, Casal JI: Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics. 2010, 10: 940-952.PubMed
25.
van der Weyden L, Rust AG, McIntyre RE, Robles-Espinoza CD, Del Castillo Velasco-Herrera M, Strogantsev R, Ferguson-Smith AC, McCarthy S, Keane TM, Arends MJ, Adams DJ: Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene. 2012, 10.1038/onc.2012.56. Epub ahead of print
26.
Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA: Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 2005, 436: 2212226-CrossRef
27.
Skrzypczak M, Gorycam K, Rubet T, Paziewska A, Mikula A, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J: Modelling oncogenic signalling in colon tumors by multidirectional analyses of microarry data directed for maximization of analytical reliabilty. PLoS One. 2010, 5i: e13091-CrossRef
28.
Su H, Hu N, Yang HH, Wang C, Takikita M, Wang QH, Giffen C, Clifford R, Hewitt SM, Shou JZ, Goldstein AM, Lee MP, Taylor PR: Global gane expression profiling and validation in esophageal squamous cell carcinoma and wiht clinical phenotypes. Clin Cancer Res. 2011, 17: 2955-2966. 10.1158/1078-0432.CCR-10-2724PubMedCentralCrossRefPubMed
29.
Landi MT, Dracheva T, Rotunno MC, Figueroa JD, Liu H, Dasgupta A, Mnn FE, Fukuoka J, Hames M, Bergen AW, Murphy SE, Pesatori AC Yang P, Consonni D, Bertazzi PA, Wacholder S, Shih JH, Caporaso NE, Jen J: Gene expression signature of cigarette smoking and its role in long adenocarcinoma devalopment and survival. PLoS One. 2008, 3: e1651 10.1371/journal.pone.0001651PubMedCentralCrossRefPubMed
30.
Buchholz M, Braun M, Heidenblut A, Kertler HA, Klōppel G, Schmiegel W, Hahn SA, Luttges J, Gress TM: Transcipthelial neoplastic lesion. Oncogene. 2005, 24: 6626-6636. 10.1038/sj.onc.1208804CrossRefPubMed
31.
Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Goirdana TJ, Misek DE, Chang AC, Zhu CQ, Strumpt D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki , Pennell N, Wier B, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dubbin KK, Lively T, Jacobson JW, Beer DG, : Gene expression based survival prediction in lung adenocarcinoma: a multi-site blinded validation study. Nat Med. 2008, 14: 822-827. 10.1038/nm.1790PubMedCentralCrossRefPubMed
Metadata
Title
Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1
Authors
Louise van der Weyden
Mark J Arends
Alistair G Rust
George Poulogiannis
Rebecca E McIntyre
David J Adams
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-29

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue

Research

miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer

Research

Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival

Research

Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells

Research

Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence

Retraction Note

Retraction Note: Application of cytology and molecular biology in diagnosing premalignant or malignant oral lesions

Erratum

Erratum to: Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits